Nolan Wages

Dr. Nolan Wages

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2014 in Journal of Biopharmaceutical Statistics
Verified
Journal Article
Closed access
NWNolan Wages
Nolan Wages
CTChristopher Tait
Christopher Tait
In dose-finding trials of chemotherapeutic agents, the goal of identifying the maximum tolerated dose is usually determined by considering information on toxicity only, with the assumption that the highest safe dose also provides the most promising outlook for efficacy. Trials of molecularly targeted agents challenge accepted dose-finding methods because minimal toxicity may arise over all doses under consideration and higher doses may not result in greater response. In this article, we propose a new early-phase method for trials investigating targeted agents. We provide simulation results illustrating the operating characteristics of our design.

22 August 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
NWNolan Wages
Nolan Wages
CCCodruta Chiuzan
Codruta Chiuzan
KPKatherine Panageas
Katherine Panageas
Background With numerous and fast approvals of different agents including immune checkpoint inhibitors, monoclonal antibodies, or chimeric antigen receptor (CAR) T-cell therapy, immunotherapy is now an established form of cancer treatment. These agents have demonstrated impressive clinical activity across many tumor types, but also revealed different toxicity profiles and mechanisms of action. The classic assumptions imposed by cytotoxic agents may no longer be applicable, requiring new strategies for dose selection and trial design. Description This main goal of this article is to summarize and highlight main challenges of early-phase study design of immunotherapies from a statistical perspective. We compared the underlying toxicity and efficacy assumptions of cytotoxic versus immune-oncology agents, proposed novel endpoints to be included in the dose-selection process, and reviewed design considerations to be considered for early-phase trials. When available, references to software and/or web-based applications were also provided to ease the implementation. Throughout the paper, concrete examples from completed (pembrolizumab, nivolumab) or ongoing trials were used to motivate the main ideas including recommendation of alternative designs. Conclusion Further advances in the effectiveness of cancer immunotherapies will require new approaches that include redefining the optimal dose to be carried forward in later phases, incorporating additional endpoints in the dose selection process (PK, PD, immune-based biomarkers), developing personalized biomarker profiles, or testing drug combination therapies to improve efficacy and reduce toxicity.

28 January 2014 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
NWNolan Wages
Nolan Wages
MCMark R. Conaway
Mark R. Conaway

3 June 2013 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
PDF file
NWNolan Wages
Nolan Wages
MCMark R. Conaway
Mark R. Conaway

29 February 2016 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
GPGina R. Petroni
Gina R. Petroni
NWNolan Wages
Nolan Wages
GPGautier Paux
Gautier Paux
FDFrédéric Dubois
Frédéric Dubois

18 April 2016 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
AIAlexia Iasonos
Alexia Iasonos
NWNolan Wages
Nolan Wages
MCMark R. Conaway
Mark R. Conaway
KCKen Cheung
Ken Cheung
YYYing Yuan
Ying Yuan
JOJohn O'QUigley
John O'QUigley